Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020
Preprint
- 15 January 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Background There is an urgent need to better understand whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection. Methods A large multi-centre prospective cohort was recruited from publicly funded hospital staff in the UK. Participants attended regular SARS-CoV-2 PCR and antibody testing (every 2-4 weeks) and completed fortnightly questionnaires on symptoms and exposures. At enrolment, participants were assigned to either the positive cohort (antibody positive or prior PCR/antibody test positive) or negative cohort (antibody negative, not previously known to be PCR/antibody positive). Potential reinfections were clinically reviewed and classified according to case definitions (confirmed, probable, possible (subdivided by symptom-status)) depending on hierarchy of evidence. Individuals in the primary infection were excluded from this analysis if infection was confirmed by antibody only. Reinfection rates in the positive cohort were compared against new PCR positives in the negative cohort using a mixed effective multivariable logistic regression analysis. Findings Between 18 June and 09 November 2020, 44 reinfections (2 probable, 42 possible) were detected in the baseline positive cohort of 6,614 participants, collectively contributing 1,339,078 days of follow-up. This compares with 318 new PCR positive infections and 94 antibody seroconversions in the negative cohort of 14,173 participants, contributing 1,868,646 days of follow-up. The incidence density per 100,000 person days between June and November 2020 was 3.3 reinfections in the positive cohort, compared with 22.4 new PCR confirmed infections in the negative cohort. The adjusted odds ratio was 0.17 for all reinfections (95% CI 0.13-0.24) compared to PCR confirmed primary infections. The median interval between primary infection and reinfection was over 160 days. Interpretation A prior history of SARS-CoV-2 infection was associated with an 83% lower risk of infection, with median protective effect observed five months following primary infection. This is the minimum likely effect as seroconversions were not included. Funding Department of Health and Social Care and Public Health England, with contributions from the Scottish, Welsh and Northern Irish governments.Keywords
This publication has 31 references indexed in Scilit:
- Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack RateJournal of Clinical Microbiology, 2020
- Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure settingPublished by Cold Spring Harbor Laboratory ,2020
- Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome SequencingClinical Infectious Diseases, 2020
- DNA vaccine protection against SARS-CoV-2 in rhesus macaquesScience, 2020
- Setting the criteria for SARS-CoV-2 reinfection – six possible casesJournal of Infection, 2020
- Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescentsmedRxiv, 2020
- SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three monthsPublished by Cold Spring Harbor Laboratory ,2020
- Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workersThe Lancet, 2020
- A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of diseasePublished by Cold Spring Harbor Laboratory ,2020
- Early Spread of SARS-Cov-2 in the Icelandic PopulationPublished by Cold Spring Harbor Laboratory ,2020